Skip to main content
LQDA logo

LQDA · Liquidia Corp

Track LQDA — free
$56.73 +0.36 (+0.64%) At close · Nov 17
Market Cap
$5.11B
Shares
90.11M
Volume · Nov 17 1.91M Avg daily vol (3M) 3.49M

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$56.73 Open$56.49 Day$54.80–57.21 52W close$25.91–91.03 Avg vol 30d4.1M Short int17.5M · 19.4% of shares · 5.3d Short vol37% Last earningsNov 10, 2026 DataJan 2020–Nov 2026 Filing10-Q · Nov 10

Up next

Mar 4, 2027 Est · unconfirmed · in 15 wks

Latest documents

2026
Nov 17
Investor event
Targets over 50% operating margins in 2027 after October settlement

Liquidia says its October settlement with United Therapeutics gives certainty, and its October 2026 referral rate was 75% of its Q3 daily rate. It plans over 50% operating margins in 2027 and 10 clinical trials next year, three registrational.

4 source passages
And this is why the settlement that we entered into in October was so important. If you look at our referral rate in October of 2026, it was 75% of where we were in Q3 on a daily rate. We're planning to do that while also achieving over 50% operating margins in 2027. And this time next year, our plan is to have 10 clinical trials in place, three of which are going to be registrational trials. Open the document at this passage
Nov 10
Earnings call
Eutrepia sales rise 31% to $222.7 million

Liquidia reported Eutrepia third-quarter net product sales of $222.7 million, up $52 million, or 31% from last quarter. A $389.7 million settlement charge drove a $236.3 million net loss, while cash ended at $396.1 million before settlement payments.

4 source passages
Net product sales of Eutrepia were $222.7 million, up $52 million, or 31% from last quarter. In total for the quarter, we reported a gap net loss of $236.3 million, which reflects a one-time settlement charge of $389.7 million, of which $380.7 million is payable in cash through April of 2027. Cash and cash equivalents continue to build through the third quarter, ending with $396.1 million prior to the settlement payments, up $111.9 million from second quarter. Welcome to the Liquidea Corporation Third Quarter 2026 Financial Results and Corporation Update Conference Call. Open the document at this passage
Nov 10
Current report 8-K
Settlement charge drives $236.3 million quarterly net loss

Liquidia Corporation reported a $236.3 million net loss for the third quarter of 2026, including a $389.7 million litigation settlement charge. Its October 13, 2026 global settlement with United Therapeutics resolved pending lawsuits and kept YUTREPIA available without disruption.

Financial results, Other events
3 source passages
Net loss for the third quarter of 2026 was $236.3 million, which includes a $389.7 million charge related to the litigation settlement. On October 13, 2026, Liquidia entered into a global settlement agreement with United Therapeutics Corporation (United Therapeutics), which resolved all six pending lawsuits between the companies. Under the settlement, YUTREPIA remains available to patients without disruption, and no patients are required to discontinue. Open the document at this passage
Nov 10
Quarterly report 10-Q FY2026 Q3, ended Sep 30
UTC settlement requires $330.4 million payments and removes PH-ILD indication

Liquidia settled all outstanding litigation with United Therapeutics Corporation (UTC) on October 13, 2026, agreeing to pay $330.4 million and remove PH-ILD from YUTREPIA’s label. Nine-month product sales rose to $523.0 million, while cash and equivalents reached $396.1 million.

Revenue $225.3M ▲ 314.6% Net loss $236.33M Diluted EPS -$2.64
Read from the MD&A section
6 source passages
On October 13, 2026, we entered into the Settlement Agreement with UTC resolving, without admission of liability by either party, all ongoing litigation between us and UTC Under the Settlement Agreement, we will continue to market, sell and promote YUTREPIA for the treatment of PAH. In exchange, we (a) filed a supplement with the FDA to amend the current product label of YUTREPIA to remove PH-ILD as an indicated treatment Litigation settlement, net was $389.7 million for the three and nine months ended September 30, 2026 and reflects charges recorded for the settlement of our litigation with UTC and the related agreements with Sandoz, Henderson, and PBM, consisting of $330.4 million payable to UTC, less $10.0 million receivable from UTC Product sales, net, were $523.0 million for the nine months ended September 30, 2026, compared to $58.2 million for the nine months ended September 30, 2025. As of September 30, 2026, we had cash and cash equivalents of $396.1 million, stockholders’ deficit of $25.4 million, and an accumulated deficit of $735.1 million. Under the Sandoz Agreement, Liquidia made a payment of $21.75 million (the “Sandoz Payment”) into escrow on October 14, 2026 Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$621.87M
Trailing 12 months
Net income (TTM)
−$94.19M
Trailing 12 months
Revenue growth YoY
+314.6%
Year over year
Operating margin
-15.6%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
5.7%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+3.7%
Year over year · more shares
Price change (1Y)
+99.8%
Trailing year
Short interest
19.4%
Latest settlement · 5.3 days to cover
View all 125 metrics

AI Brief

Q3 FY26 earnings call · Nov 10, 2026
Q3 FY26

TL;DR. YUTREPIA net product sales increased 31% to $222.7 million, adjusted EBITDA reached $140.5 million for a fifth consecutive quarterly increase, cash reached $396.1 million before settlement payments, and October shipments reached their highest level since launch. Risks include the $389.7 million settlement charge and $380.7 million cash obligation, PH-ILD label removal and promotion cessation, referral volatility, higher R&D and SG&A expenses, and the settlement's limited protection for future indications and products.

Bullish
  • + Third-quarter net product sales increased 31% to $222.7 million, including $212.2 million of paid patient demand. new
  • + Cash and cash equivalents increased to $396.1 million before settlement payments. new
  • + The prescriber base reached approximately 1,300, with greater depth of prescribing and expanding PAH adoption. new
Bearish
  • − Third-quarter GAAP net loss was $236.3 million, reflecting a $389.7 million litigation settlement charge. new
  • − The settlement does not protect indications beyond PAH or new treprostinil products, and United Therapeutics may assert patents against development programs. new

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Mentioned in fund letters

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Buy Momentum Neutral Sentiment Bearish Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 25.5 · fear Equity put/call 0.71
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg +3%
above
Price vs 50-day avg +17%
above
RSI (14) 65
neutral
MACD trend Positive
52-week position 47%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Neutral
1-month return +56%
trailing
6-month return −9%
trailing
YTD return +64%
this year
Relative strength −6%
vs S&P · 6-mo
Sentiment
smart money
Bearish
Trend (MA cross) No cross
50d $48 › 200d $55 — 200d above 50d
Institutional flow Distributing
-10% holders QoQ · +63 funds added
Insider flow Distributing
Net -$7.6M over 90 days · 100% sells
Short interest Rising
19.43% of shares out · ▲ +1.2% MoM · 5.3 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
310 holders — mid 3-yr range
Squeeze score 81
high risk · 0–100
Fundamentals
Strong
Revenue growth +1031%
Y/Y
EPS growth +51%
Y/Y
Free cash flow $-40.0M
Quant / Vol
risk profile
Very High
Volatility 93%
annualized · 1-yr
Max drawdown −72%
past year
ATR 6.6%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the 8-K filed Nov 10, 2026
Settlement payment · 2026 and 2027 $380.7M
Previous outlook earlier release · from the Earnings Call filed Mar 31, 2026

Still-open targets the latest release did not restate under the same label.

At least $1 billion in 2027 · in 2027 at least $1B

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Buy
0 · 4 · 3
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+3% Bullish
Price vs 50-day avg
+17% Bullish
RSI (14)
65 Neutral
MACD trend
Positive Bullish
52-week position
47% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bearish · 3 of 6
Trend (MA cross) No cross
50d $48 › 200d $55 — 200d above 50d
Institutional flow Distributing
-10% holders QoQ · +63 funds added
Insider flow Distributing
Net -$7.6M over 90 days · 100% sells
Short interest Rising
19.43% of shares out · ▲ +1.2% MoM · 5.3 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
310 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $26 Now $57 · 47% Range high $91
vs 200-day avg +3% vs 50-day avg +17%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Paid patient demand $212.2M third quarter of 2026 —
Prescriber base 1,300 through October 2026 —
prescribers 1,300 Q3 2026 —
Prescribers who have written a PAH script since launch 77% since launch —
Prescribers who have written for two or more patients 60% as of October 31, 2026 —
Referrals including a PAH diagnosis 70% September 2026 —
YUTREPIA prescribers 1,300 Launch to Date (LTD) through Oct'26 —
Annualized net product sales run-rate $682M exited Q2 2026 —
Patients started on treatment since launch in June 2025 5,000 between launch in June 2025 and July 31, 2026 —
Prescribers who referred patients for YUTREPIA 1,100 through 31-Jul 2026 —
Prescribers with 5+ referrals 30% through 31-Jul 2026 —
Prescription to patient start conversion rate 85% as of July 31, 2026 —
Total number of prescribers since launch 1,100 as of July 31, 2026 —
Unique patient prescriptions (YUTREPIA) 5,900 through 31-Jul 2026 —
Unique patient prescriptions since launch in June 2025 5,900 between launch in June 2025 and July 31, 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Drug Manufacturers - Specialty & Generic — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
LQDA
Liquidia Corp
this stock
$5.11B +64.5% +1031.2% — 19.4%
TAK
Takeda Pharmaceutical Co Ltd
$69.14B +38.8% — — 0.1%
GALDY
Galderma Group AG
$52.00B +7.6% — — 0.0%
TEVA
Teva Pharmaceutical Industries Ltd
$49.73B +36.6% +4.3% 96.9 2.4%
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
$40.66B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
310
% held
83.6%
Net QoQ
+2.8M sh
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
288
View
Short & Settlement
Short Interest Rising
Shares short
17.5M
Days to cover
5.3d
Change
+207.6K sh
View
Short Volume
Short vol %
37%
As of
Nov 17, 2026
Short Total
View
Fails to Deliver
FTD shares
496
Value
$21.7K
As of
Oct 27, 2026
View
Off-Exchange
Off-exchange %
48.2%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$7.6M
Buyers / Sellers
0 / 2
Buyers Sellers
View
Financials
Financials
Revenue (FY)
$158.3M
Net income (FY)
$-68.9M
EPS diluted
$-0.80
View
Filings
SEC Filings
Latest
Investor Event Transcript
Filed
Nov 17, 2026
This year
22

Liquidia says its October settlement with United Therapeutics gives certainty, and its October 2026 referral rate was 75% of its Q3 daily rate. It plans over 50% operating margins in 2027 and 10 clinical trials next year, three registrational.

View
Proposed Sales
Value
$560.2K
Shares
8.5K
Filed
Sep 14, 2026
View
Exempt Offerings
Offering
$21.7M
Filed
Apr 16, 2021
View
Earnings & Events
Webcasts
Last webcast
Nov 17, 2026
View
Investor Relations
Latest news
Liquidia Corporation Reports Thir…
Published
Nov 10, 2026
View

Performance

5D 20D 120D MTD YTD
LQDA +10.4% +56.1% -8.5% +25.9% +64.5%
SPY -2.3% -4.8% -2.9% -3.1% +7.4%
vs SPY +12.7% +60.8% -5.6% +29.0% +57.1%
Key facts CIK 1819576 CUSIP 53635D202 13F (30d) 317 filings 291 filers Visit website Investor relations